Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort.

TitleStatin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort.
Publication TypeJournal Article
Year of Publication2009
AuthorsBrown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA
JournalAntivir Ther
Volume14
Issue6
Pagination853-8
Date Published2009
ISSN1359-6535
KeywordsAdipose Tissue, Adult, Aged, Anti-HIV Agents, Body Composition, Cohort Studies, Female, Hip, HIV-Associated Lipodystrophy Syndrome, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged
Abstract

BACKGROUND: We aimed to determine whether statin exposure in antiretroviral-treated individuals is associated with increases in hip circumference compared with HIV treatment without concomitant statin use.

METHODS: This was a prospective multicentre cohort study involving individuals who had received antiretroviral therapy for at least 40 weeks and who were enrolled in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. There were 2,223 participants in the statin-unexposed group and 371 in the statin-exposed group. The main outcome measure was change in hip circumference at week 32.

RESULTS: The 32-week change in hip circumference in the statin-exposed group was 0.60 cm greater (95% confidence interval 0.11-1.10; P=0.02) than in the statin-unexposed group after adjustment for age, gender, race, baseline body mass index and thymidine analogue exposure.

CONCLUSIONS: Our findings support the hypothesis that statins might be beneficial in lipoatrophy. Given the limited treatment options for this important problem, further studies are needed to confirm this effect and to determine its clinical significance.

DOI10.3851/IMP1300
Alternate JournalAntivir. Ther. (Lond.)
PubMed ID19812448
PubMed Central IDPMC2865258
Grant List5K23AT2862 / AT / NCCIH NIH HHS / United States
AI068634 / AI / NIAID NIH HHS / United States
AI069465 / AI / NIAID NIH HHS / United States
AI069501 / AI / NIAID NIH HHS / United States
K23 AT002862 / AT / NCCIH NIH HHS / United States
K23 AT002862-05 / AT / NCCIH NIH HHS / United States
M01 RR000051 / RR / NCRR NIH HHS / United States
M01 RR000051-441193 / RR / NCRR NIH HHS / United States
M01 RR000052 / RR / NCRR NIH HHS / United States
M01 RR000052-430842 / RR / NCRR NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01 AI068636-04S1 / AI / NIAID NIH HHS / United States
U01 AI069465 / AI / NIAID NIH HHS / United States
U01 AI069465-04 / AI / NIAID NIH HHS / United States
U01 AI069501 / AI / NIAID NIH HHS / United States
U01 AI069501-04 / AI / NIAID NIH HHS / United States